Robert W. Baird Forecasts Strong Price Appreciation for Agenus (NASDAQ:AGEN) Stock

Agenus (NASDAQ:AGEN) had its price objective raised by Robert W. Baird from $3.00 to $4.00 in a research report sent to investors on Tuesday morning,Benzinga reports. They currently have a neutral rating on the biotechnology company’s stock.

Other equities analysts have also issued research reports about the stock. StockNews.com raised shares of Agenus from a “sell” rating to a “hold” rating in a research note on Friday, March 21st. HC Wainwright restated a “neutral” rating on shares of Agenus in a report on Wednesday, April 30th. Finally, B. Riley reiterated a “buy” rating on shares of Agenus in a report on Monday, April 21st. Six equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $9.00.

Agenus Stock Down 3.4%

Shares of NASDAQ AGEN opened at $3.38 on Tuesday. Agenus has a 12 month low of $1.38 and a 12 month high of $19.69. The company has a market cap of $71.56 million, a price-to-earnings ratio of -0.30 and a beta of 1.48. The business has a fifty day simple moving average of $2.17 and a 200-day simple moving average of $2.91.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings data on Monday, May 12th. The biotechnology company reported ($1.03) EPS for the quarter, beating analysts’ consensus estimates of ($1.61) by $0.58. The firm had revenue of $24.07 million for the quarter, compared to analysts’ expectations of $26.38 million. As a group, sell-side analysts expect that Agenus will post -12.55 EPS for the current fiscal year.

Institutional Investors Weigh In On Agenus

Hedge funds and other institutional investors have recently made changes to their positions in the company. Corton Capital Inc. bought a new stake in shares of Agenus in the 4th quarter valued at approximately $36,000. Apollon Wealth Management LLC raised its position in Agenus by 25.0% during the first quarter. Apollon Wealth Management LLC now owns 25,007 shares of the biotechnology company’s stock valued at $38,000 after acquiring an additional 5,000 shares in the last quarter. Virtu Financial LLC acquired a new stake in Agenus in the fourth quarter valued at approximately $51,000. Bank of Montreal Can bought a new stake in Agenus in the fourth quarter worth approximately $69,000. Finally, Invesco Ltd. acquired a new position in shares of Agenus during the 1st quarter worth $88,000. 61.46% of the stock is owned by hedge funds and other institutional investors.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.